Trial · NCT03334058
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
NCT03334058, Phase 2, Completed, argenx
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus. Trials, record NCT03334058. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03334058
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
- NCT number
- NCT03334058
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- argenx
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus
- Interventions
- ARGX-113
- First posted
- 2017-11-07
- Last updated
- 2020-12-14
- Other registries' IDs
- eudract:2017-002333-40
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and tolerability as measured by the incidence and severity of treatment-emergent (serious) adverse events over the study. | Up to 6 months | |
| Secondary | Evaluation of serum levels of total IgG and subtypes (IgG1, IgG2, IgG3, IgG4) | Up to 6 months | |
| Secondary | Evaluation of serum levels of anti Dsg-1 and -3 autoantibodies | Up to 6 months | |
| Secondary | Pemphigus Disease Area Index (PDAI) | Up to 6 months | The score has a range from 0 to 263, the higher the score, the more severe the disease. |
| Secondary | Time to disease control (DC), control being defined as the absence of new lesions and established lesions beginning to heal | Up to 6 months | |
| Secondary | Time until relapse, relapse being defined as the appearance of 3 or more new lesions a month that do not heal spontaneously within 1 week, or as the extension of established lesions | Up to 6 months | |
| Secondary | Pharmacokinetic parameters of ARGX 113: Tmax | Up to 6 months | |
| Secondary | Pharmacokinetic parameters of ARGX 113: Cmax | Up to 6 months | |
| Secondary | Incidence of anti-drug antibodies (ADA) to ARGX 113 | Up to 6 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03334058
GET https://conductscience.org/api/trials/v1/NCT03334058/registered